OncoMatch/Clinical Trials/NCT06315257
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Is NCT06315257 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PVX7 for cervical cancer.
Treatment: PVX7 — A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IVA
advanced (stage IB1-IVA) cervical cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgical resection — primary
completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months
Must have received: radiation therapy — primary
completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months
Must have received: platinum-based chemotherapy — primary
completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months
Lab requirements
Blood counts
white blood cell count ≥ 3,000; lymphocyte number ≥ 500; absolute neutrophil count ≥ 1,000; platelets ≥ 90,000; hemoglobin ≥ 9
Kidney function
creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
Liver function
total bilirubin <1.5 X ULN, <3 x ULN if Gilbert's disease; AST/ALT <3 X ULN
Adequate organ function as defined by the following parameters: white blood cell count ≥ 3,000; lymphocyte number ≥ 500; absolute neutrophil count ≥ 1,000; platelets ≥ 90,000; hemoglobin ≥ 9; total bilirubin <1.5 X ULN, <3 x ULN if Gilbert's disease; AST/ALT <3 X ULN; creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Alabama at Birmingham · Birmingham, Alabama
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify